![xbar elite xbar elite](https://megaproteinstore.gr/image/cache/catalog/data/Products/dymatize/dymatize-elite-protein-bar-70-gr-15-items-1100x1100.jpg)
Erez Shor said, “The severe complications associated with AI leaks cost the healthcare system in excess of $7 Billion annually. The diagnostic monitoring system developed by Exero Medical is intended to provide timely intervention that could save lives and improve the prognosis of hundreds of thousands of patients as well as save the healthcare system billions of dollars every year,” said Professor Nir Wasserberg, M.D., Chair of the Israel Colorectal Society and Director, Division of Colorectal Surgery, Department of Surgery, Beilinson Campus, Rabin Medical Center.“Įxero Medical CEO Dr. Mortality depends on how early a leak is detected and how quickly intervention begins.
![xbar elite xbar elite](https://cdn.shopify.com/s/files/1/1415/2424/products/cb231-016-back_09219281-7ac2-4137-9df5-aa6e2c582c1e_500x.jpg)
Of those, up to 40%, will need multiple revision surgeries, longer hospitalization stays in terms of weeks and, frankly some won’t make it. Of the more than five million patients undergoing GI surgery every year, as many as 10% percent could develop this devastating complication. “An anastomotic leak is the most fretted complication of colorectal surgery. The data collected will be used to refine the system’s machine-learning algorithms and evaluate the system against the institutional standard of leak diagnosis. It is first being utilized for the early detection of anastomotic (AI) leaks following low anterior resection gastrointestinal surgery. XBar is a sensor designed to track tissue healing internally from the surgical site following an operation. Ian White, Shimon Dolnikov and Alberto Moran, with the Exero Medical team after the first implantation at Beilinson Campus, Rabin Medical Center
![xbar elite xbar elite](https://cdn.shopify.com/s/files/1/0321/2066/8291/products/IMG_2202_620x.jpg)
Or Yehuda, Israel, MaExero Medical has enrolled the first patient in its multi-center safety and feasibility study of the company’s flagship product, the xBar tissue monitoring and diagnostic system.ĭrs.